AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02408146 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intravenous infusion pump of patient-controlled analgesia
Description: The third group has oral celecoxib before surgery, and receives 40 mg parecoxib sodium intravenously guttae immediately after surgery, then uses new intravenous infusion pump of patient-controlled analgesia (parecoxib sodium 1 mg/mL + normal saline) for three days after surgery. The pump is infused continuously at the basic flow rate of 2 mL/h, 0.5 mL of bolus can be injected if the patients press the button once upon experiencing pain. The lock-out time for each bolus injection is 15 minutes.
Study NCT03914339 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: periodontal treatment
Description: Eighteen periodontally compromised patients who give be given periodontal treatment alone.
Study NCT04710693 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CAD polyp-detection system
Description: Software will be used during the procedure to aid the detection of polyps during the procedure.
Study NCT02408146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl citrate+ ondansetron hydrochloride + normal saline
Study NCT02408146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Study NCT03952923 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CAR-T cells
Description: CD19-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
Study NCT02949661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Superficial cervical plexus block
Description: Patients will receive bilateral superficial cervical plexus block
Study NCT02949661 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local wound infiltration
Description: Patients will receive local wound infiltration
Study NCT02391727 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: SYN004
Description: subjects who have received effective treatment for their cancers are eligible
Study NCT01299597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 20mg single dose given alone and coadministered with SB649868 on day 8 and 12 of the 14-day repeat dose period.
Study NCT01299597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 10mg single dose given alone and coadministered with SB649868 on day 12 and 14 of the 14-day repeat dose period.
Study NCT01299597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB649868
Description: 20mg daily given for 14 days.
Study NCT03524365 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RYGB
Description: Roux-\&-Y Gastric Bypass (RYGB) involves the use of a surgical stapler to create a small and vertically oriented gastric pouch with a volume of 30 ml. The upper pouch is completely divided by the gastric remnant and is anastomosed to the jejunum, 75 cm distally to the Treitz's ligament , through a narrow gastrojejunal anastomosis in a Roux-en-Y fashion. Bowel continuity is restored by an entero-entero anastomosis, between the excluded biliary limb and the alimentary limb, performed at 100 cm from the gastrojejunostomy. Lifestyle modification counselling is provided to each patient.
Study NCT03524365 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SG
Description: The SG is created using a linear stapler with two sequential 4.8/60-mm green load firings for the antrum, followed by two or three sequential 3.5/60-mm blue loads for the remaining gastric corpus and fundus. The stapler is applied alongside a 48-Fr calibrating bougie. The resection line is performed avoiding the ''critical area'' by resecting the fundus 1.5 cm from the angle of His. Staple lines are buttressed with bovine pericardial strips. The resected stomach is grasped at the antral tip by a laparoscopic grasper and retrieved through one of the trocar sites. A methylene blue dye test by a nasogastric tube is routinely performed at the end of the procedure. The residual gastric remnant capacity is 60-80 ml. Drains are not routinely placed, and the nasogastric tube is removed at the end of the procedure. Upper gastrointestinal contrast (Gastrografin) study is performed on the first postoperative day. Lifestyle modification counselling is provided to each patient.
Study NCT03524365 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Intensive Lifestyle Modification
Description: Resting calorie requirements will be calculated via the Harris Benedict equation (24) and an activity factor, and subjects will be instructed not to change their activity level other than that suggested by physicians during the study. The diet will contain 1/3 kcal less than the calculated energy expenditure and 30% fat of which 10% saturated, 55% lower glycemic index carbohydrates and 15% proteins.~The participants will be encouraged to gradually increase their walking to achieve 10,000 steps per day. A moderate intensity physical activity program of 1 hour of aerobic exercise 2-3 hours per week will be recommended to all subjects. Their physical activity will be assessed by IPAQ-SF.
Study NCT03962998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose/Rhamnose solution
Description: Lactulose/Rhamnose solution administered orally followed by measurement of excreted lactulose and rhamnose in urine
Study NCT03962998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102
Description: MB-102 solution administered orally followed by measurement of excreted MB-102 in urine
Study NCT01645930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules
Study NCT01645930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide capsules
Study NCT01645930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets
Study NCT00797927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: quetiapine (with equivalent dose to original antipsychotic agent) would replace the original antipsychotic agent for 28 days
Study NCT00797927 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: no intervention
Description: keep the original conventional antipsychotic agent for 28 days
Study NCT00277472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan/Hydrochlorothiazide
Description: 160/12.5 mg taken once daily orally
Study NCT00277472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCTZ
Description: 25 mg taken once daily orally
Study NCT03774017 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: one-staged hybrid operation
Description: An integrated procedure that consists of microsurgery, intraoperative DSA, endovascular intervention techniques and other assistance tools. All the procedures are performed in a one-staged operation without any intermission or any transfer of patients.
Study NCT03774017 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Traditional microsurgical operation
Description: The classical mode of operations in neurosurgery. The operation is performed with neurosurgical instruments and microscope. Some of assisting tools can be used in the operation, such as neuro-navigation, Doppler probe, neural electrophysiological monitoring and so on. But neither the intraoperative DSA nor endovascular intervention techniques is used in the operation
Study NCT02020343 — intervention group
Intervention type: BEHAVIORAL
Intervention: taste tests
Description: Subjects undergo sham feeding in which they take a bit of food, chew it and spit it out. This test should engage sensory mechanisms which may affect intestinal signaling.
Study NCT02868502 — intervention group
Intervention type: DEVICE
Intervention: Goldmann tonometer
Description: IOP measurement in the sitting position and lateral decubitus
Study NCT01800409 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AFES
Description: During the stimulation sessions electrical stimulation will be applied for 40 minutes per day, 5 days per week for a total of 8 weeks
Study NCT01154036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg
Study NCT02868502 — intervention group
Intervention type: DEVICE
Intervention: Pneumatonometer
Description: IOP measurement in the sitting position and lateral decubitus
Study NCT01154036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Study NCT01154036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Study NCT02868502 — intervention group
Intervention type: DEVICE
Intervention: Tonopen XL
Description: IOP measurement in the sitting position and lateral decubitus
Study NCT00107263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Study NCT01154036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: rosuvastatin
Study NCT01418092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 37
Description: Capsules for oral administration
Study NCT01418092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules for oral administration
Study NCT03795805 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total knee arthroplasty
Description: Total knee arhroplasty
Study NCT03795805 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: total knee arthroplasty
Description: Total knee arhroplasty
Study NCT03795805 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tourniquet limb cuff
Description: Tourniquet limb cuff and regular anesthesia
Study NCT03795805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intaarticular lidocain
Description: 20 ml of 2% lidocain application intraarticular before surgery (intraarticular lidocain)
Study NCT03672864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive exercise
Description: Intensive, child-initiated movement of the lower extremity: 1 hour/day, 4 days/week, 2 sessions delivered by a physical therapist, 2 delivered by a parent. All activities are play based, and exercise intensity is enhanced by small weights placed on the dorsum of the foot and the ankle of the affected limb. Intervention is delivered over 12 weeks for a target of 48 hours of training.
Study NCT00655395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laromustine (VNP40101M) and Ara-C
Description: 1. Laromustine 300 mg/m2 (cohort 1), 400 mg/m2 (cohort 2), 500 mg/m2 (cohort 3) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~2. Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion.
Study NCT01896011 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide 20 mcg
Description: Teriparatide 20 mcg injection pen
Study NCT01896011 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 20 mcg injection pen
Study NCT01307852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plastic Scintillation Detectors
Description: Radiation detectors attached to rectal balloon for each CT scan done during each radiation treatment. Treatment delivery Monday through Friday for 7 weeks.
Study NCT02075983 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GTU®-multiHIV B clade
Description: The investigational HIV-1 vaccine GTU®-MultiHIV B clade encodes for a MultiHIV antigen (synthetic fusion protein built up by full-length polypeptides of Rev, Nef, Tat, p17 and p24 with more than 20 Th and CTL epitopes of protease, reverse transcriptase (RT) and gp160 regions of the HAN2 HIV-1 B clade.
Study NCT02075983 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GTU®-multiHIV B clade
Description: The investigational HIV-1 vaccine GTU®-MultiHIV B clade encodes for a MultiHIV antigen (synthetic fusion protein built up by full-length polypeptides of Rev, Nef, Tat, p17 and p24 with more than 20 Th and CTL epitopes of protease, reverse transcriptase (RT) and gp160 regions of the HAN2 HIV-1 B clade.
Study NCT03300089 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anaesthesia
Description: General anaesthesia
Study NCT03300089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional anaesthesia
Description: Regional anaesthesia
Study NCT00983619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551
Description: MEDI-551 will be administered intravenously (IV) once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
Study NCT02868502 — intervention group
Intervention type: DEVICE
Intervention: ICare rebound tonometer
Description: IOP measurement in the sitting position and lateral decubitus
Study NCT01019408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Comparison of two different dosages of chloroquine for treatment of falciparum malaria in Afghan refugee camps in Northwest Frontier Province, Pakistan
Study NCT03358862 — intervention group
Intervention type: DEVICE
Intervention: NaturalVue Multifocal Contact Lens
Description: NaturalVue multifocal contact lenses are daily disposable, distance center, multifocals with a novel extended depth of focus optical design. Patients wearing their habitual corrections who opt to change to this new lens will have their myopia progression monitored for up to two years.
Study NCT01500174 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultraviolet therapy UV254
Description: three times per week until wound closure or patient discharge from hospital
Study NCT01500174 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ultraviolet therapy UV254
Description: Three times per week irradiation of wound base and periwound skin
Study NCT01499238 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal SIMV
Description: rate: 30-50/min, PIP: 16-20, PEEP: 4-6, FİO2: 40%
Study NCT02637180 — intervention group
Intervention type: DRUG
Intervention: anti-osteoporotic medication
Description: check previous information
Study NCT02044939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program
Description: Pulmonary rehabilitation program should follow ATS/ERS Guidelines (2006)
Study NCT03567551 — intervention group
Intervention type: OTHER
Intervention: Women w/ Preeclampsia w/o Visual Disturbances or Headache
Description: Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant
Study NCT00983619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered IV on Days 1, 8, 15, and 22 (28- day cycle). The treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches complete response or withdraws consent.
Study NCT02034084 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: left radial approach
Description: Coronary diagnostic procedures performed through left radial approach
Study NCT02034084 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right radial approach
Description: coronary diagnostic procedures performed through right radial approach
Study NCT04387890 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serologic SARS-CoV-2 screening
Description: Quantitative Indirect Chemiluminescence Immunoassay (CLIA) to access SARS-CoV-2 specific IgM and IgG serum antibody level every 2 weeks during follow up
Study NCT00691028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-650 3 mg/kg
Description: 3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6. Then 3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
Study NCT01499238 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal CPAP
Description: PEEP: 4-6 mmHg, FİO2: 40%
Study NCT00691028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-650 6 mg/kg
Description: 3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6 weeks. Then 6 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
Study NCT00691028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-650 10 mg/kg
Description: 3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6. Then 10 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
Study NCT00890630 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracervical Balloon Catheter
Description: Intracervical insertion of an 80cc Double-Balloon Catheter.
Study NCT00890630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: IV Oxytocin infusion, dose dependent on patient response. Start at 2mIU/min, increasing every 30 minutes by 2mIU/min, to max 24mIU/min.
Study NCT00890630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: IV Oxytocin infusion, dose dependent on patient response. Start at 2mIU/min, increasing every 30 minutes by 2mIU/min, to max 24mIU/min.
Study NCT02273310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-Solving Skills Training for Disease Management
Description: Children and caregivers participated in a multi-family group to learn problem-solving skills as applied to disease management and school functioning in the context of sickle cell disease.
Study NCT01001494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 200 μg bid
Description: Aclidinium bromide 200 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks
Study NCT01001494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 400 μg bid
Description: Aclidinium bromide 400 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks
Study NCT01001494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice-daily by inhalation for 24 weeks
Study NCT04022369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Group
Description: The intervention group received 45-60 minute of individual training and a handbook for the exercise program was given. These patients were followed for a total of 12 weeks. The weekly motivational phone calls structured according to the empowerment model and home visits when necessary were repeated. The exercise program was developed by reviewing the literature part on physical activity for senior citizens with heart failure. The program was established on evidence-based recommendations for the cardiac rehabilitation of patients with HF. Each session included warm-up and cool-down exercises, moderate walking, and balance exercises.
Study NCT01373645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yinyi stent
Description: subjects with Yinyi stent implantation
Study NCT00738192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl citrate
Description: Fentanyl 0.5 μg/kg delivered intravenously immediate at the end of remifentanil pump finished
Study NCT00738192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil citrate
Description: Sufentanil 0.05 μg/kg delivered intravenously immediate at the end of remifentanil pump finished
Study NCT00738192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Butorphanol tartrate
Description: Butorphanol 0.01 mg/kg delivered intravenously immediate at the end of remifentanil pump finished
Study NCT03503851 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MitraClip implantation
Description: Device to approximate the mitral valve leaflets
Study NCT01083927 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotational Narrow Strip Conjunctival Graft
Description: Surgical technique
Study NCT01083927 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full Conjunctival Graft
Description: Surgical technique
Study NCT04389970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Feeding
Description: Participants will eat all food within an 8 hour window each day. They will only consume water or black coffee during the remaining 16 hours.
Study NCT04993222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B liposome for injection
Description: IV infusion
Study NCT03567551 — intervention group
Intervention type: OTHER
Intervention: Women w/ Preeclampsia w/ Visual Disturbances or Headaches
Description: Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant
Study NCT03567551 — intervention group
Intervention type: OTHER
Intervention: Women w/o Preeclampsia
Description: Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant